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INTRODUCTION 
HIV / AIDS in India is moving from high risk groups to the more 
vulnerable segments among the general population.  There are an 
estimated 5.7 million HIV positive cases  in 20051.   
Political commitment has shifted significantly in favour of 
providing access to antiretroviral therapy for people living with HIV / 
AIDS.  Treatment is now perceived as a critical component of a 
comprehensive programme to combat HIV / AIDS, along with 
prevention and the improvement of health care infrastructure for the 
delivery and monitoring of care and support. 
‘The Call to Action’ at the UN general assembly special session 
on HIV / AIDS pushed forward s new global consensus on the need for 
Antiretroviral Therapy.  World Health Organization released guidelines 
for antiretroviral use in resource constrained settings in April 2002 and 
added 10 ART drugs to its list of essential medicines for all countries.  
WHO declared the lack of access to ARV treatment for HIV / AIDS a 
‘Global Health Emergency’ in September 2003 and announced that it 
would release an emergency plan to scale up access to ARV treatment 
for atleast three million people by the end of 2005 (popularly known as 
the 3 by 5 initiative). 
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Role of Antiretroviral Therapy: 
 ART is no cure for HIV / AIDS.  Effective antiretroviral 
regimens inhibit the efficient replication of the HIV virus and reduces 
viraemia to undetectable levels.  Lower frequency of opportunistic 
infections significantly reduces the cost of management of HIV.  This 
helps people to lead more productive lives, with perceptibly reduced 
stigma and discrimination.  Success achieved in terms of ART delaying 
the onset of AIDS has now transformed the common perception about 
HIV from being an immediately fatal source to a some what more 
manageable, chronic illness, although devastatingly debilitating in the 
long run. 
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JUSTIFICATION 
 HIV / AIDS is an infectious disease that is also considered to be 
chronic disorder.  The health related quality of life or health status has 
become an important consideration in the treatment of patients with 
chronic disorders.  The purpose of medical intervention for chronic 
diseases is defined as improvement in both the quantity and quality of 
life.  The former corresponds to an improvement in mortality, where as 
the latter indicates improvement in the (HRQOL) Health related quality 
of life.  The importance of HRQOL as a health index especially in the 
evaluation of health care services for the treatment of chronic disorders, 
has long been emphasized.  However, there have been few reports 
examining the HRQOL in AIDS patients. 
 Anti-retroviral increase the AIDS - free time, delay and decrease 
opportunistic infections but may have intolerable side effects and the 
effect of anti-retroviral on long-term survival is unclear.  So it would be 
just to examine the quality of life of patients on anti-retroviral therapy 
and compare it with their pre ART quality of life. 
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REVIEW OF LITERATURE 
 
MILE STONES: 
 
1981- Acquired immunodeficiency syndrome (AIDS) was first 
recognized as a new disease in the United States when 
clinicians in New York, Los Angeles, and San Francisco 
began to see young, homosexual men with Pneumocystis 
carinii pneumonia (PCP) and Kaposi's sarcoma (KS), 
unusual diseases for young adults not known to be 
immunosuppressed. The first report in the medical 
literature that alerted the world to this new 
immunodeficiency syndrome appeared in June of 1981 
and described five young, homosexual men in Los 
Angeles with PCP2. 
1983- Human Immunodeficiency Virus (HIV) was first isolated 
in France in 1983 by Françoise Barré-Sinoussi in the 
laboratory of Luc Montaignier as lymphadenopathy-
associated virus (LAV)3. 
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1984- The virus was also isolated in San Francisco in 1984 by 
Jay Levy and named it AIDS Associated retrovirus4.  
1986 -  First case of HIV infection was detected in India among 
commercial sex workers in Madras. 
1986- Discovery of HIV – 2 virus in West Africa by 
Montaignier’s group 5. 
1986- National AIDS Committee was formed to guide and 
advice the Govt. of India in Prevention and Control of 
HIV/AIDS.  
1987- National AIDS Control Programme (NACP) was 
launched. 
1992- National AIDS Control Organisation (NACO) was setup 
as a semi- autonomous body by the Govt. of India. 
1992- Launching of NACP Phase I (1992-1999) with following 
objectives: 
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 1. Involve all States and Union Territories in developing 
HIV/AIDS preventive activities with a special focus on the 
major epicenters of the epidemic. 
2. Attain a satisfactory level of public awareness on HIV 
transmission and prevention. 
3. Develop health promotion interventions among risk 
behaviour groups. 
4. Screen all blood units collected for blood transfusions. 
5. Decrease the practice of professional blood donations. 
6. Develop skills in clinical management, health education 
and counselling, and psychosocial support to HIV 
seropositive persons, AIDS patients and their associates. 
7. Strengthen and control of Sexually Transmitted 
Diseases (STD) and 
8. Monitor the development of the HIV/AIDS epidemic in 
the country. 
1999- Launching of NACP Phase II ( 1999-2006 ) with the 
following objectives: 
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1. To shift the focus from raising awareness to changing 
behaviour through interventions, particularly for groups at 
high risk of contracting and spreading HIV. 
2. To support decentralization of service delivery to the 
State and Municipalities and a new facilitating role for 
National AIDS Control Organization. Program delivery 
would be flexible, evidence-based, participatory and to 
rely on local programme implementation plans. 
3. To protect human rights by encouraging voluntary 
counseling and testing and discouraging mandatory 
testing. 
4. To support structured and evidence-based annual 
reviews and ongoing operational research, and 
5. To encourage management reforms, such as better 
managed State level AIDS Control Societies and improved 
drug and equipment procurement practices. These reforms 
are proposed with a view to bring about a sense of 
‘ownership’ of the programme among the States, 
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Municipal Corporations, NGOs and other implementing 
agencies. 
2003- The "3 by 5" initiative, launched by UNAIDS and WHO 
in 2003, was a global TARGET to provide three million 
people living with HIV/AIDS in low- and middle-income 
countries with life-prolonging antiretroviral treatment 
(ART) by the end of 2005. It was a step towards the 
GOAL of making universal access of HIV/AIDS 
prevention and treatment accessible for all who need them 
as a human right. 
2004- The government on the eve of the World AIDS Day, 2003, 
announced its programme for free distribution of ARVs in 
selected states. In June 2004, the Global Fund on AIDS, 
TB and Malaria awarded a financial grant of US $ 165 
million to provide ART in the public sector and through 
public-private partnershipsfor 1,00,000 people living with 
AIDS over a five year period.  
2006- NACP Phase III(2006-2011). The overall goal of NACP 
III is to halt and reverse the epidemic in India over the 
next 5 years by integrating programmes for prevention, 
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care, support and treatment. This will be achieved through 
four strategic objectives namely: 
1. Prevention of new infections in high risk groups and 
general population through: 
a. Saturation of coverage of high risk groups with   
targeted interventions (TIs) 
b.  Scaled up interventions in the general population 
2. Increasing the proportion of people living with 
HIV/AIDS who receive care, support and treatment. 
3. Strengthening the infrastructure, systems and human 
resources in prevention and treatment programmes at the 
district, state and national levels. 
4. Strengthening a nation-wide strategic information 
management system. 
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BURDEN OF THE DISEASE: 
There are an estimated 38.6 million people living with HIV world 
wide – 4.1 million newly infected in 2005, 2.8 million died of AIDS in 
20051.  
In India the estimated number of cases is 5.7 million HIV cases 
and 2.7 to 6.8 lakh deaths (2005) due to AIDS. 
The national adult prevalence is 0.8 % of the 35 states of India 6 
states, four in southern India  (Andhra Pradesh, Tamil Nadu, 
Maharastra, Karnataka) and two in north eastern India (Manipur and 
Nagaland) have generalized epidemic with HIV prevalence rate of above 
1% among pregnant women1. 
The prevalence in Tamil Nadu has dropped to below 1 % (2005 
sentinel surveillance report NACO). These six states account for nearly 
80 % of all reported AIDS cases in the country. 
India has a large number of people living with HIV/AIDS, second 
to South Africa.  
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NATURAL HISTORY OF THE DISEASE: 
The natural history of any disease refers to the stages through 
which a disease passes, in the absence of any intervention.  Clear 
knowledge of natural history of a disease helps in identifying the stages 
at which appropriate intervention for prevention or control of the disease 
can be undertaken. 
Pre-pathogenesis period 
The Agent 
Human Immune deficiency Virus (HIV) 
 HIV belongs to the family of retro viruses 
 There are two types of HIV virus: Type 1 and Type 2 
 Both types are prevalent in India, Type 1 is more frequently 
reported. 
 HIV Type 1 is a more virulent pathogen than type 2. 
 HIV type 2 is generally milder, slower to progress and poorly 
transmitted vertically. 
 Virus is found in almost all body fluids and organs. 
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 But they are present in very large numbers in semen, vaginal and 
cervical secretions and blood. 
 The central nervous system, testes, lymph nodes act as reservoirs 
of HIV. 
 The highest concentration of HIV among the body fluids is found 
in cerebrospinal fluid. 
 
HOST FACTORS 
AGE AND SEX 
The spread of HIV infection occurs most frequently in the 
sexually active and economically productive age group of 15 to 44 
years.  Globally during 2004 the male to female ratio is nearing equal.  
In India according to NACO, however, the male to female ratio is 3:1. 
APAC sponsored community prevalence study in Tamil Nadu during 
1998 shows the HIV infected cases between males and females to be 
equal. 
Factors involved in the risk of acquisition of infection 
¾ Number of sexual partners 
¾ Frequency of “at risk” sexual exposures 
¾ Local HIV prevalence rates among core groups and bridge 
population, etc. 
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¾ Consistent use of condoms 
¾ Presence of sexually transmitted diseases in any of the partners. 
High-risk behaviors 
Based on the epidemiological characteristics of HIV infection, 
certain high-risk behavior groups, who are likely to be harboring 
infection more frequently than the general population, have been 
identified. 
¾ People with multiple sex partners (Commercial sex workers, men 
who are away from their families for long periods, as they are 
likely to have extra marital sex) and homosexuals. 
¾ Injecting drug users, because they share needles and syringes. 
¾ People requiring frequent transfusions of blood e.g. 
hemophiliacs, thalassemics etc. 
Transmission routes 
1. Sexual Transmission 
 The current worldwide expansion of AIDS epidemic is primiarily 
driven by sexual transmission of HIV-1.  In the most populous 
regions of the world, sexual transmission among hetro sexuals is 
the dominant mode of spread6 sexual transmission among 
homosexual men is still a significant part of epidemic spread in 
United States and Europe7. 
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2. Injection Drug Usage 
HIV could be isolated from blood – contaminated needles, 
syringes and injection paraphernalia which provides a biologic 
rationale for HIV transmission among IDU8.  This is an important 
route of transmission in North Eastern States of India. 
3. Transmission by Blood, Blood Products, Tissue 
Transplantation and Artificial Insemination. 
Transmission of HIV-1 can occur following transfusion of a 
blood product derived from an infected person’s blood and 
processed into a blood component (i.e. whole blood, packed cells, 
fresh frozen plasma, cryoprecipitate and platelets9. 
4. From infected mother to her baby 
Transmission from infected pregnant mother to the baby mainly 
during the perinatal period and through breast milk.   
5. Needle stick exposure 
Accidental exposure in health care settings or in procedures like 
tattooing etc., Needle stick / sharp injuries are a comparatively 
rare mode of transmission.  There are only few such cases 
reported in the world despite the fact that millions of health care 
workers are knowingly or unknowingly handling HIV infected 
individuals.  Despite 
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such a low risk, the unrealistic fear remains as a major hurdle in 
extending health care to the HIV infected individuals.  The risk 
depends upon the concentration of virus in those body fluids, the 
depth of injury, the type of needle (with solid or hollow bore) 
Immunogenic status of the patient and the precautions followed 
thereafter. 
EFFICACY OF VARIOUS MODES OF TRANSMISSION 
Sl. 
No. 
Modes of 
transmission Efficacy 
Source of 
infection 
1 Sexual intercourse 0.1 – 1.0% 80 - 86% 
2 Blood transfusion 90 – 95% 3 – 5% 
3 Perinatal 20 – 40% 2 – 3% 
4 Injecting drug use 0.5 – 1.0% 3 – 5% 
5 Needle stick exposure Less than 
0.1% 
 
 
Pathogenesis 
 
The natural history of HIV infection begins as soon as virus 
enters the body of a susceptible host through any of the routes of 
transmission as discussed earlier (sexual, parenteral and perinatal) 
¾ HIV infects predominantly T helper (CD4) Lymphocyte 
¾ As the numbers and functions of CD4 cells decline, immune 
deficiency sets in  
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¾ As immune deficiency progresses, the subject develops 
secondary (opportunistic) infections and malignancies and further 
constitutional signs and symptoms of the diseases contracted 
¾ 5-10% of HIV individuals are long-term non-progressor and live 
for more than 10 years. 
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Upto three months of HIV infection, there is often an 
asymptomatic viraemia, during which period although patients are 
infective, ELISA test for HIV antibodies are negative.  Progression to 
symptomatic disease i.e., the amount of time it takes from HIV infection 
to become full blown AIDS depends on the general health and 
nutritional status before and during the time of HIV infection 10. 
WINDOW PERIOD 
Lasts for 6 weeks to 12 weeks 
HIV antibodies reach a high titer approximately 3 months after 
the virus has entered the body.  If the tests like RAPID test, ELISA & 
Western Blot are performed within three months, they may be reported 
as negative.  This is known as the window period.  However the patient 
will be in a carrier state transmitting the disease to others by all routes 
mentioned. 
CD4 COUNT AND VIRAL LOAD: 
Depletion of CD4+ T lymphocytes is the hall-mark and the 
apparent source of the central immune defect of HIV disease, 
determination of the CD4 lymphocyte count (or percentage) has been 
the most important laboratory marker of disease progression.  Absolute 
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CD4 lymphocyte count or percentage correlates strongly with AIDS – 
defining disease, has been included in the surveillance case definition of 
AIDS since 1993, and has been used to set indications for therapy.  The 
CD4 lymphocyte count declines from a normal value of around 1,000 
cells to an AIDS-defining level of 200/µL over a mean of about 8 to 9 
years in a young adult, but there is a great deal of individual variability 
in this general pattern. 
The measurement of the number of viral copies per milliliter of 
peripheral blood (commonly known as “viral load”) has been made 
possible by the development of sensitive assays using polymerase chain 
reaction or nucleic acid sequence – based amplification of the viral 
source or branched DNA amplification of the signal that can detect virus 
down to a few hundred copies per milliliter in the most commonly used 
tests and down to a few copies per milliliter in the latest ultrasensitive 
tests.  I was known from earlier viral detection tests, such as assays for 
p24 antigen and quantitative assays for the antibodies to the p24 antigen, 
that measures of viral activity were strong predictors of AIDS in 
asymptomatic HIV-infected persons independent of the CD4 
lymphocyte count11,12.  The newer measures of viral quantity are even 
stronger predictors of disease and provide a clinically useful range of 
values that can monitor the effectiveness of antiviral therapies in 
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controlling viral replication.  Their prognostic usefulness has been 
demonstrated in prospective studies by associating levels of viral 
quantity in peripheral blood and changes in viral quantity with 
subsequent development of AIDS and death13.  The association has been 
shown in both recent seroconverters and asymptomatic HIV-infected 
persons and in subjects from different HIV transmission groups14.  
Plasma HIV RNA levels are orders of magnitude lower in long-term 
non-progressors than in subjects with progressive disease.  Undetectable 
HIV RNA in peripheral blood is associated with stable CD4 lymphocyte 
counts and increases in HIV RNA correlate with rate of CD4 
lymphocyte cell decline14,15.  Peripheral blood viral load is changed by 
anti-retroviral therapy, often dropping below the level of assay detection 
in persons who begin receiving combination therapy16. 
WHO CLINICAL STAGING17 : 
Clinical stage 1 
¾ Asymptomatic  
¾ Persistent generalized lymphadenopathy 
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Clinical stage 2 
¾ Unexplained moderate weight loss (<10% of presumed or measured 
body weight) 
¾ Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis 
media, pharyngitis)  
¾ Herpes zoster  
¾ Angular cheilitis 
¾ Recurrent oral ulceration  
¾ Papular pruritic eruptions 
¾ Seborrhoeic dermatitis  
¾ Fungal nail infections 
Clinical stage 3 
¾ Unexplained severe weight loss (>10% of presumed or measured 
body weight) 
¾ Unexplained chronic diarrhoea for longer than one month 
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¾ Unexplained persistent fever (above 37.5oC intermittent or constant 
for longer than one month 
¾ Persistent oral candidiasis  
¾ Oral hairy leukoplakia  
¾ Pulmonary tuberculosis 
¾ Severe bacterial infections (e.g. pneumonia, empyema, pyomyositis, 
bone or joint infection, meningitis, bacteraemia,) 
¾ Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
¾ Unexplained anaemia (<8 g/dl ), neutropenia (<0.5 x 109 /L) and or 
chronic thrombocytopenia (<50 X 109 /L3) 
Clinical stage 4 
¾ HIV wasting syndrome  
¾ Pneumocystis pneumonia  
¾ Recurrent severe bacterial pneumonia   
¾ Chronic herpes simplex infection (orolabial, genital or anorectal of 
more than one month's duration or visceral at any site) 
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¾ Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
¾ Extrapulmonary tuberculosis  
¾ Kaposi's sarcoma 
¾ Cytomegalovirus infection (retinitis or infection of other organs) 
¾ Central nervous system toxoplasmosis 
¾ HIV encephalopathy 
¾ Extrapulmonary cryptococcosis including meningitis 
¾ Disseminated non-tuberculous mycobacteria infection   
¾ Progressive multifocal leukoencephalopathy  
¾ Chronic cryptosporidiosis 
¾ Chronic isosporiasis  
ANTI-RETROVIRALS 
The advent of ART in the late 1980’s began a revolution to 
change HIV from being a killer disease to one of manageable chronic 
illness.  The primary aim of ART strategies is to suppress viral 
replication.  Successful viral suppression restores the immune system, 
slows or halts disease progression and improves quality of life.  Studies 
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in Brazil have shown that there is an improvement in AIDS related 
mortality and morbidity due to universl accesses of ART in Brazil.  
Quality of life in individuals receiving Anti-retroviral therapy is related 
to adherence18. 
Adherence is a major factor which can determine the success of 
ART programme as well as to prevent development of HIV drug 
resistance.  Adherence is necessary to ensure sustained viral suppression 
on the available first line regimen, because when resistance occurs 
treatment becomes increasingly complicated and costly. 
The Government of India launched a free ART programme on 1st 
April 2004 and has since adopted the public health approach to 
administration and distribution of ART17.  Section of first line regimen 
is determined on the basis of a number of considerations such as 
potency, profile of side effects, ability to keep future treatment options 
open, ease of adherence, cost, risk during pregnancy and potential of 
resistant viral strains.  The current global recommendation in all 
circumstances is a trifle drug regimen19. 
KEY GOALS OF THE NATIONAL CARE AND TREATMENT 
PROGRAMMES: 
o To provide long term ARV Therapy to eligible patients 
o To monitor and report treatment outcome 
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o To attain individual drug adherence rates of 95% and more 
o To increase the lifespan and quality of life of PLHAS. 
Eligibility for ART:  
The national programme offers antiretroviral therapy to following 
group of people: 
¾ All persons with HIV infection who are clinically eligible to 
receive ART  
¾ Those who are already on ART (outside the national programme) 
and want to get enrolled into the National ART  programme 
according to the available national ART regimens after written 
informed consent 
Strengthening of linkages and referrals with the Prevention of 
Parent to Child Transmission (PPTCT) programme will be done in order 
to expand treatment access to women as well as children living with 
HIV/AIDS. The national programme will link with other programmes 
such as the Revised National TB Control Programme (RNTCP), 
Reproductive and Child Health (RCH), National Rural Health Mission 
(NRHM) and others. 
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Goals of Therapy 
 
¾ Clinical Goals: Prolongation of life and improvement in 
quality of life. 
¾ Virologic Goals: Greatest possible reduction in viral load for 
as long as possible.  
¾ Immunologic Goals: Immune reconstitution that is both 
quantitative and qualitative.  
¾ Therapeutic Goals: Rational sequencing of drugs in a fashion 
that achieves clinical, virologic and immunologic goals while 
maintaining treatment options, limit drug toxicity and facilitate 
adherence. 
¾ Epidemiologic Goals: Reduce HIV transmission. 
 
When to start antiretroviral therapy in adults and adolescents17 
 
All persons registered for care and treatment at the ART centers 
should have a full history and clinical examination which include 
clinical staging. The principle for initiation of ART is based on clinical 
staging with CD4 to guide treatment and follow-up. Lack of a CD4 
result should not delay initiation of ART if the patient is medically 
eligible for this, but a CD4 test should be done as soon as possible. 
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The following group of persons will undergo a CD4 test to screen for 
ART eligibility17: 
 
¾ All positive persons with WHO clinical stages 3 and 4. 
¾ All persons tested HIV positive 6-8 years ago 
¾ PLHAs with history of pulmonary TB and/or herpes zoster in the 
past. 
¾ If CD4 has been done from private lab and is less than 350 cells/mm3 
¾ HIV infected  partners of AIDS patients 
¾ All pregnant HIV-positive  women 
¾ All HIV positive children (< 15 years old) 
 
WHO Clinical classification of established HIV infection17 
 
HIV associated 
symptomatology 
WHO clinical 
stage 
Treatment 
Guideline 
Asymptomatic 1 CD4 guided 
Mild symptoms 2 CD4 guided 
Advanced symptoms 3 CD4 guided 
Severe/advanced symptoms 4 Treat irrespective 
of CD4 
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Treatment Guideline as per CD4 Count17 
 
CD4 (cell /mm3) Actions 
< 200 Treat irrespective of clinical stage 
200 – 350 
Offer ART for symptomatic patients 
Initiate before drop below 200   cells/mm3* 
>350 Defer treatment in asymptomatic persons 
 
* If CD4 is between 200-250, this should be repeated in 4 weeks and 
treatment to be considered in asymptomatic patients. Current global 
evidence and WHO guidelines recommend that patients be initiated on 
ART before CD4 drops below 200 cells/mm3. 
What to start:  
 
Currently, the national programme will make a limited number of 
first line regimen combinations available. Drug combinations available 
under the National Programme are: 
(i) Stavudine(30mg)+Lamivudine(150mg)+ Nevirapine(200 mg) 
(ii) Stavudine(40 mg)+Lamivudine(150mg)+  Nevirapine(200 mg) 
(iii) Zidovudine(300mg)+Lamivudine(150mg)+ Nevirapine(200 mg) 
(iv) Stavudine(30 mg) + Lamivudine(150mg)  
(v) Stavudine(40 mg) + Lamivudine(150mg)  
(vi) Zidovudine (300mg) + Lamivudine(150mg)  
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(vii) Efavirenz (600mg) 
(viii) Nevirapine (200 mg) 
Fixed dosed combinations (FDCs) are preferred because they are easy 
to use, have distribution advantages (procurement and stock 
management), improves adherence of intake of ARVs and thus reduces 
the changes of development of HIV drug resistance. Current national 
experience showed that BID (twice a day) regimens with FDCs are well 
tolerated and complied with.  
The first-line ART regimens recommended under the national 
programme are: 
 AZT (Zidovudine)    Nevirapine (NVP) 
        Or        + Lamivudine (3TC) +              Or 
 D4T (stavudine)     Efavirenz (EFV) 
 
The recommended choices of first line regimens should be given in 
the following priority17: 
 
a. AZT + 3TC + NVP/EFV (for patients with Hb > 8 g/dl) for (60% of 
total patients) 
b. d4T + 3TC + NVP/EFV (for 40% of total patients) 
c. TDF + 3TC + NVP/EFV.  This combination is for special situations 
only when there is toxicity/other contraindications to AZT or d4T. 
This combination will be provided on a case-to-case basis at SACS 
level for a limited number of patients. This will be decided by an 
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expert panel at SACS consisting of two physicians with experience 
in ART, one SACS representative and one INP representative. (To 
be discussed with DG) 
Efavirenz (EFV) should be given to following group of persons: 
a. PLHA receiving concurrent anti-tuberculous drugs (ATT) for the 
duration of the anti-TB treatment 
b. Where there is clinical or laboratory evidence of hepatic dysfunction 
eg. due to hepatitis B/C co-infection or other causes 
EFV is contraindicated in pregnant HIV – infected women during the 
first trimester of pregnancy because of concerns of teratogenicity. 
CLINICAL AND LABORATORY MONITORING17 
With the advent of scaling up of treatment nationally as well as 
increased awareness of HIV and access to counseling and testing 
services, it is envisioned that there would be an increase in PLHAs not 
requiring ART as many more would have presented in an earlier stages 
of disease. Experience of current ART centers showed that there is a 
need to emphasize good HIV (pre-ART) care and support so as to 
maintain wellbeing. 
a) Pre-ART care: is defined as the period where a HIV positive person 
is well and does not medically require initiation of ART. It is 
expected that with the scaling up of the national programme and 
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numbers of Counseling and testing centers, the shift from AIDS 
patients to HIV persons will occur. For PLHAs who do not need 
ART, they should be advised and counseled to maintain healthy/ 
 positive living.  
 In order to follow up and monitor these patients such that early 
detection of opportunistic infections (OIs) and initiation of ART before 
the CD4 declines to below 200 cells, the following is recommended as 
routine monitoring of patients who are not yet eligible for ART: 
1. Comprehensive clinical evaluation:   
2. Laboratory work up of pre- ART care patients:   
• HIV-infected persons should have a baseline screening CD4 
where possible. 
• Laboratory work-up:  
i. Mandatory: CBC, ALT/AST, ALP, serum creatinine, CXR, 
VDRL/TPHA; urinalysis 
ii. For women: PAP smear screening annually or acetic acid 
cervical screening at district healthcare facilities 
iii. Screen HBsAg and HCV for IDUs/ transfusion-associated 
infections or those with liver enzyme elevations 
iv.  Attention should be given to screen TB 
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Services to be offered for pre-ART Care patients should include 
family screening and counseling of partners and children as well as 
follow-up of discordant couples, support, linkages, tracing defaulters 
etc.  
 These patients should be registered in the NACO Pre-ART 
Register . 
b)   Routine Monitoring of  patients on ART 
a) Recommendations on the follow up and monitoring schedule for 
patients on ART in the national programme: 
Monitoring and follow up schedule for patients on ART17 
 Day 0 
(baseline) 
At 
15 
days 
At    1 
month 
At  2 
month 
At   3 
month 
At    6 
month 
Clinical and 
adherence 
counseling 
X X X X X X 
Hb X X ( if 
on 
AZT) 
X (if on 
AZT) 
 X X 
ALT X X (in 
on 
NVP) 
X (if on 
NVP) 
 X * 
 
X* 
Urinalysis X     X (if on 
TDF) 
Lipid profile X (if on 
EFV and 
PI) 
    X (if on 
d4T, EFV 
or PI) 
Random 
Blood sugar 
X     X (if on PI) 
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 Pregnancy testing for women with pregnancy potential (if 
planning for EFV)      
* For HBV and/or HCV co-infected patients, 3-monthly 
screening of liver function is recommended. 
FOLLOW UP OF CD4 SCHEDULE 
CD4 count Repeat CD4 every 
< 350 3 months 
> 350 6 months 
on ART 6 months 
> 500 For operational research or 
consider suggesting annually 
which allows for recording a 
steep decline in some cases 
 
• If CD4 between 200 to 250, the repeat in 4 weeks and consider 
treatment 
 Once a patient is on an effective and stable regimen at 6 months, 
quarterly follow up is recommended where adherence is reasonably 
ascertained. 
b) Clinical follow up of patients on ART : follow with high index of 
clinical suspicion to Screening new opportunistic infections (OI) and 
adverse drug reactions appropriate to the regimen given. 
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Major toxicities of first line ARV regimens and drug substitutions 
 
Regimen Toxicity Drug Substitution 
D4T/3TC/NVP • d4T – related neuropathy or 
pancreatitis 
• d4T –related lipoatrophy 
• NVP –related severe hepatotoxicity 
• NVP – related severe rash (but not life 
threatening)  
• NVP –related life threatening rash 
(Stevens – Johnson syndrome) 
• Switch d4T to ZDV 
 
• Switch d4T to TDF or 
ABC (if available) 
• Switch NVP to EFV 
(except in pregnancy) 
 
• Switch NVP to EFV 
 
• Switch NVP to PI 
AZT/3TC/NVP • ZDV –related persistent GI intolerance 
or severe haemtological toxicity 
• NVP –related severe hepatoxicity 
• NVP –related severe rash (but not life 
threatening) 
• NVP –related life threatening rash 
(Stevens - Johnson syndrome) 
• Switch ZDV to d4T 
 
 
• Switch NVP to EFV 
(except in pregnancy. 
In this situation switch 
to NFV, LPV/r or 
ABC.) 
• Switch NVP to EFV 
 
• Switch NVP to PI 
D4T/3TC/EFV • d4T –related neuropathy or pancreatitis
• d4T –related lipoatrophy 
• EFV –related persistent CNS toxicity 
• Switch d4T to ZDV 
• Switch d4T to TDF or 
ABC 
• Switch EFV to NVP 
AZT/3TC/EFV • ZDV –related persistent GI intolerance 
or severe hematological toxicity 
• EFV – related persistent CNS toxicity 
• Switch ZDV to d4T 
• Switch EFV to NVP 
Note: Substituting D4T (ie. patient is off D4T) may not reverse 
lipodystrophy but may slow its progression. Besides AZT -  TDF, ABC 
or ddI are acceptable alternatives but may not be available in the 
national programme. 
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ADHERENCE TO ANTIRETROVIRAL THERAPY17 
Studies of drug adherence in the developed world have suggested 
that higher levels of drug adherence are associated with improved 
virological and clinical outcomes and that rates 95% are desirable to 
maximise the benefits of ART. It is a challenge to achieve rates this high 
over a long period of time. Interventions that improve treatment 
adherence and safe behaviour are: 
(i) The decision to enroll a patient into the ART programme should 
be based on the patient's medical and psycho-social parameters.  
(ii) Education and counseling: Once the person is enrolled in the 
ART programme, the physician and counselor should educate the 
persons about the possible side effects of drugs, follow-up dates 
and importance of adherence to ARV treatment and 
consequences of non-adherence.  During every follow-up visit to 
ART clinic, the patient should also be asked to bring drugs along 
with him so that the pills can be counted in order to assess the 
level of adherence.  
(iii) ART clinic counselors should maintain a register of all visits.  
During every visit the patient should be counselled on adherence 
of ARV treatment and in case of any side effects of drugs the 
patients should be referred to treating physician. Counselors 
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should be part of the training programme on ARV treatment and 
they should be trained properly in monitoring of adherence to 
ARV treatment.  Counselor should also emphasize that ART is 
merely a treatment and not a cure and the need to practice safe 
sexual behaviour, with consistent condom use. It might be useful 
to ensure condom availability during every visit of the HIV/AIDS 
patients on ARV treatment. 
(iv) Participation of Family Members / guardian:  Patient should be 
motivated to bring a family member or guardian along at the time 
of commencing ARV treatment.  The guardian should be 
educated about the illness and the need for lifelong treatment and 
adherence to drugs.  They should be encouraged to accompany 
patients on the follow-up visit, if possible.  All efforts should be 
made to encourage guardian supported ARV treatment so that the 
adherence of therapy could be ensured. 
(v) Reminders in case of drop out:  In case the patient does not visit 
the ARV treatment unit on the scheduled fixed date, 
NGOs/Networks of PLHAs should be involved to contact the 
patient or guardian in a confidential manner to mobilize the 
patient to continue treatment.  The role of communities and 
NGOs in mobilizing communities to support adherence is 
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extremely important. Maintaining confidentiality and privacy are 
of utmost importance. 
(vi) Involvement of Primary Health Care Systems: A patient residing 
in a rural area would find it difficult to re-visit the district 
hospital for follow-up.  
(vii) Depending upon the patients attached to a PHC/CHC, ARV drugs 
should be made available by the district hospital.  However, 
patient should be referred from PHC/CHC to district hospital 
once in six months for laboratory investigations and opinion of 
the treating physician. 
(viii) Treatment adherence may be more difficult in pregnant women 
and in immediate post partum period.  Pregnancy associated 
morning sickness and gastro-intestinal upset may complicate 
ART and this may be further complicated by side effects 
associated with ARV drugs.     Family support would be essential 
for ensuring adherence to ARV treatment.   
(ix) Treatment adherence in children is a special challenge, 
particularly if family unit is disrupted by health or economic 
conditions.  As currently, pediatric formulations are not widely 
available for all ARV drugs, WHO recognizes that until 
appropriate formulations can be made more widely available, the 
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splitting of adult dose formulation of ARV drugs, should be 
considered 
Key to successful adherence strategies is the proper education of 
the patient before the initiation of therapy, support ARV initiation as 
patient first starts medications and continuously monitor and support 
adherence. Reinforcement of adherence principles to the patient by 
treatment supporters (guardian), relatives, friends and community 
support personnel is of great help.  
QUALITY OF LIFE: 
 
Quality of life is a term that is popularly used to convey an 
overall sense of well being and includes aspects such as happiness and 
satisfaction with life as a whole19. 
World Health Organisation has defined QOL as individuals’ 
perceptions of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, standards, 
expectations and concerns20. 
Health Related Quality of life (HR – QOL) refers to a patient’s 
physical and mental well being over time.  It is defendant on disease 
symptoms, treatment efficacy in relieving symptoms and treatment 
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related side effects21.  The evaluation of HR-QOL originated with the 
European Organization for Research and Treatment of Cancer (EORTC) 
which designed instruments to assess patient well being during cancer 
clinical trials22. 
Assessment of QOL has been traditionally done in chronic 
diseases like cancer, diabetes, schizophrenia and in patients who have 
undergone surgeries.  But in recent years, health relative QOL has been 
an important consideration in virtually all situations resulting in 
deviation from normal health including QOL assessment in HIV 
infected individuals.  Studies have been carried out to see the effect of 
antiretroviral therapy particularly on the major changes in the life of 
HIV infected individuals who can now look forward to many more years 
in life23.  But these extra years of life include a large pill burden, life 
style modification to accommodate the dosage schedules and to cope 
with various side effects24.  All these factors make it necessary to 
evaluate quality of life of HIV infected individuals, which provides 
valuable insights into how the disease and treatment affect the patients.      
Several instruments have been specifically developed to assess 
the QOL of people living with HIV and AIDS.  Some of these includes 
Medical Outcome Questionnaire25.  The AIDS Health Assessment 
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Questionnarie26, the general health assessment27 and the 
multidimensional quality of life questionnaire for HIV / AIDS28. 
In addition a number of generic instruments are also available 
like SF-3629 the sickness impact profile30 and the WHOQOL-100. 
Studies have been conducted to validate the QOL instruments like MOS 
(HIV)31, SF-3629 and WHOQOL-HIV31. 
The WHOQOL-HIV was pilot tested among 900 persons from 
six culturally diverse centres (Australia, Brazil, Thailand, India (New 
Delhi and Bangalore) and Zimbabwe) Subsequently, this module was 
further field tested.  Statistical analyses show that persons with HIV / 
AIDS should poorer quality of life. 
Cross-cultural applicability of instruments is a major limitation 
for their widespread use.  The WHOQOL is the only quality of life 
instrument that has been simultaneously developed in a wide range of 
cultures.  It is a cross-cultural measure that may be particularly useful 
for measurement of quality of life across different areas32,33.  The Hindi, 
Tamil and Kannada versions of WHOQOL-HIV Brief are available. 
     
 40 
METHODOLOGY 
STUDY DESIGN:  
An interventional study design -“Before and After” Comparison 
study without control. 
STUDY POPULATION: 
People Living with HIV/AIDS attending Government Hospital of 
Thoracic Medicine, Tambaram, Chennai. 
INCLUSION CRITERIA: 
Adults above the age of 18 years, of both sexes, Tamil speaking, 
who have been screened and found fit to receive Antiretroviral therapy. 
METHOD OF SCREENING FOR ART: 
PLHAs who are in Clinical Stage IV disease and PLHA’s whose 
partner is already receiving ART were counselled regarding ART and 
importance of adherence. If they are willing to take ART they are 
subjected to the following tests – CD4 count, Heamoglobin, HBsAg, 
LFT, RFT, X-Ray chest and Sputum for AFB. 
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 If their CD4 count is <200, or >200 but <350 and clinically Stage 
IV and if LFT, RFT are within normal limits they are considered fit for 
Antiretroviral therapy. These patients are registered for ART.  
SAMPLE SIZE CALCULATION: 
Wig et al34 have reported mean ( SD ) total score of quality of life 
as 48.83( 11.18 ) . 
Expecting a better quality of life after ART at the end of 3 
months, that is, a change of minimum 7.5 units (increase) in the total 
score, with alpha and beta errors at 5 % and  10 % level respectively. 
 
The required sample size will be: 
 
            N = 2 x SD ² x [ Z ( 1- α/2 ) + Z ( 1 – β ) ] ²  
   ( mean1 – mean 2 ) ² 
Where SD is  12 
mean 1 – mean 2 = 7.5 
n = 54 
Expecting a 10% drop out rate the sample to be studied will be 60. 
SAMPLING TECHNIQUE: 
Simple random sampling by lottery method at the rate of three 
persons per day of PLHA’s who have been registered for ART till the 
required sample size was reached from 18.04.06 to 12.05.06. On an 
average 10 new cases are registered for ART every day. 
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METHOD: 
After obtaining permission from the Director, Institute of 
Community Medicine, Madras Medical College, Chennai and from The 
Superintendent, Government Hospital of Thoracic Medicine, Tambaram, 
Chennai, the study was started.  
The purpose of the study was explained, confidentiality was 
assured and oral consent obtained from the participants. 
 The pre-tested Tamil version of WHOQOL-HIV BREF was 
introduced and they were requested to fill up without leaving any 
question. If they were not sure of any answer they were asked to fill up 
the nearest possible one which comes to their mind. For those who could 
not read, the questionnaire was read out, and in case of doubts, they 
were clarified by a single interviewer. Their height and weight were 
noted. 
The patients’ address, contact phone numbers was obtained. The 
mode by which they preferred to be contacted was noted. The phone 
number of the investigator was also given to everyone. Some of them 
did not want letters to be written to them as their HIV status was not 
known to people around them. They preferred to call the investigator to 
intimate their visit dates. They were requested to meet the investigator 
who would be present 20.07.06 to 20.08.06 at GHTM, Tambaram. 
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On their follow-up visit after three months (for investigations and 
collecting drugs) the WHOQOL HIV BREF was reintroduced, the 
procedure to fill being the same as before. Logistically it is not possible 
to ascertain that they have really taken their drugs.  So an ‘intention to 
treat’ analysis was done. 
During the first contact 64 PLHA’s were enrolled for the study. 
49 came for follow up between 20.07.06 and 20.08.06. Four died before 
July 2006. The remaining 11 were contacted over phone and or post as 
per their initial preference. Three preferred to have the questionnaire 
sent by post and five wanted to answer over the phone. One person did 
not return the questionnaire. The remaining three could not be contacted 
by phone or by post. So, finally 56 persons were followed up. 
The questionnaire has 31 questions pertaining to 6 domains 
namely- Physical (4 questions), Psychological (5 questions), Level of 
Independence (4 questions), Social (4 questions), Environmental (8 
questions), Personal Beliefs (4 questions), one question regarding their 
rating of their QOL and one question regarding their level of satisfaction 
about their health. Each question has a score range of 1 to 5. Twenty 
four questions have answers in such a way that the score reflects QOL. 
Seven questions have Reverse scoring. Eg. - For the Question No.3 –  
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To what extend do you feel that physical pain prevents you from what 
you need to do?  
Not at all A little A moderate amount Very much 
An extreme 
amount 
1 2 3 4 5 
 
A score of 1 indicates the best and 5 indicates the worst. 
For such questions the modified score is got by subtracting the 
obtained score from 6 (6- Obtained score) 
Thus, if the patient writes 1(Not at all), then the Modified score 
would be 6-1=5. 
Overall scores could range from 31 to155, with a higher score 
indicating better Quality of life. 
STATISTICAL ANALYSIS: 
Statistical analysis was performed using Statistical Analysis 
software SPSS. Descriptive variables such as mean and standard 
deviation are used. One-way analysis of variance (ANOVA) was 
performed for finding out significant difference between domain scores 
and demographic characteristics. Paired t-test was performed for finding 
out significant difference between pre and post-ART Quality of life 
scores. Pearson Correlation was performed to find out the correlation 
between BMI and CD4 and QOL.  
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RESULTS 
 
The Demographic Profiles of the sample population is as below; 
 
TABLE – 1 
SEX DISTRIBUITION 
 
Sex No. of Cases 
Male 34 (60.7%) 
Female  22 (39.3%) 
 
TABLE – 2 
AGE DISTRIBUTION 
Age in years No of Cases Percentage 
21-30 14 25% 
31-40 28 50% 
41-50 10 17.9% 
51-60 4 7.1% 
 
Mean Age is 36.89 and  SD is 7.88 
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TABLE-3 
MARITAL STATUS OF THE STUDY PATIENTS 
 
Marital Status No. Percent 
Single 6 10.7% 
Married 28 50.0% 
Living as married 1 1.8% 
Separated 4 7.1% 
Widowed 17 30.4% 
  
 
TABLE – 4 
PERCEPTION OF STATE OF HEALTH 
Health Status No. Percent 
Very Poor 1 1.8% 
Poor 18 32.1% 
Neither poor nor good 24 42.9% 
Good 11 19.6% 
Very Good 2 3.6% 
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TABLE-5 
MODE OF TRANSMISSION 
 Gender 
Mode Male Female 
Total 
Sex with man 2 21 23 
Sex with women 31 0 31 
Blood products 1 1 2 
Total 34 22 56 
 
 Heterosexual transmission was seen in 52 (92.86%) subjects, 
homosexual in 2 (3.57%) and transmission through blood products was 
seen in 2 (3.57%) 
TABLE-6 
YEARS AFTER DIAGNOSIS AND PRE-ART QOL 
 N Mean Std. Deviation 
Oneway 
ANOVA 
F-test 
0-1 21 62.0952 11.09912 
2-3 19 64.1579 7.51490 
4-5 13 67.2308 11.11421 
6-7 3 63.3333 2.51661 
Total 56 64.0536 9.71301 
F=0.74 
P=0.53 
 
Based on One-way ANOVA and F-test there is no statistically 
significant difference in years after diagnosis and pre ART QOL. So, the 
groups may be considered as homogenous. 
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TABLE-7 
  
Pre and  
Post-ART overall QOL scores 
Paired t-test 
t=32.45    P=0.001 ( Highly Significant) 
There was a Highly Significant improvement in the Quality of 
Life scores after ART. 
TABLE - 8 
DOMAIN-WISE PRE AND POST-ART SCORES  
  Mean 
Std. 
Deviation 
Paired 
t-test 
Pre_Physical 2.2902 .87097 Pair 1 Post_Physical 3.9330 .60395 
t=15.99 
P=0.001 
Pre_Psychological 2.3500 .69308 Pair 2 Post_Psychological 3.7429 .62285 
t=16.10 
P=0.001 
Pre_Level of 
independence 1.8348 .76615 Pair 3 Post_Level of 
independence 3.2188 .65028 
t=14.71 
P=0.001 
Pre_Social 2.4196 .60134 Pair 4 Post_Social 3.4420 .54144 
t=16.11 
P=0.001 
Pre_Environmental 2.4821 .45566 Pair 5 Post_Environmental 3.6942 .45222 
t=23.97 
P=0.001 
Pre_Personal beliefs 2.9375 .67798 Pair 6 Post_Personal beliefs 4.2634 .51217 
t=19.25 
P=0.001 
 
 Mean Std Deviation Minimum Maximum 
Pre ART 64.05 9.71 42.00 85.00 
Post ART 101.48 8.55 72.00 123.00 
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CORRELATION BETWEEN BMI AND POST TEST SCORE 
Correlation between BMI and Post test score
BMI
24222018161412
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4.0
3.5
3.0
2.5
2.0
 
 
TABLE-9 
CORRELATIONS 
 
            
* Correlation is significant at the 0.05 level (2-tailed). 
0-0.2        poor 
0.2-0.4     fair 
0.4-0.6     moderate 
0.6-0.8     good 
0.8-1.0      very good 
 
  Pretest score Posttest score 
Pearson 
Correlation .239 .321(*) 
Sig. (2-tailed) .076 .016 
BMI 
 
 
N 56 56 
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TABLE – 10   
 
COMPARISON OF MALE AND FEMALE PRE AND POST ART 
SCORES 
  Gender N Mean 
Std. 
Deviation 
Student  
t-test 
Male 34 64.7941 9.44451 Pre total 
  Female 22 62.9091 10.23025 
t=0.70 
P=0.48 
Male 34 102.5000 8.19183 Post total 
  Female 22 99.9091 9.04438 
t=1.10 
P=0.27 
 
There was no statistically significant difference between men and 
women in the baseline QOL scores.  
There was no statistically significant difference between those 
living with spouse and those without (One-way ANOVA). 
Based on One-way ANOVA the patients’ perception of his/her 
status of health correlated well (p<0.05) with the physical, psychological 
and Level of Independence domains but not with Social, Environmental 
and Personal Beliefs. 
TABLE-11 
CORRELATION BETWEEN CD4 AND QOL 
    Base line QOL 
Pearson Correlation 0.433(**) 
Sig. (2-tailed) 0.001 
CD4 
 
 N 56 
 
** Correlation is significant at the 0.01 level (2-tailed). 
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DISCUSSION 
WHO has defined quality of life as 'individual's perception of 
their position in life in the context of the culture and value systems in 
which they live and in relation to their goals, expectations, standards and 
concerns'. Quality of life is often regarded as a concept that is too 
nebulous to be measured reliably with a structured questionnaire and is 
subject to too much variability across cultures and individuals to have 
any useful validity. However, WHOQOL questionnaire developed in the 
WHOQOL project demonstrated that QOL could be conceptualized and 
defined in a uniform way across cultures. Its constituent core domains 
and facets can be assessed using structured questionnaire methodology, 
and cross-cultural as well as intra-cultural comparisons can be made. 
Physical domain assesses pain, impact of disease on activities of 
daily living, lack of energy and sleep. 
The psychological domain assesses the patients’ own thoughts, 
about body image and appearance, positive feelings like enjoyment, 
ability to concentrate, personal satisfaction and negative feelings like 
despair, anxiety and depression. 
Level of independence assesses medical treatment, mobility, 
performance of activities of living and capacity for work. 
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The Social domain assesses acceptance, personal relationships, 
social support and sexual activity. 
Environment does play a major role in determining health states. 
Environmental domain assesses influence of factors like financial 
resources, the work environment, accessibility to health and social care, 
freedom, security and participation and opportunities for leisure 
activities on the QOL 
The domain on Personal beliefs assesses the feelings like 
meaningfulness in life, discrimination, fear of future and death. 
The study shows that there is a significant improvement in the 
QOL of patients after three months of starting ART. This is in line with 
other studies35. Other studies have shown that women have lower QOL 
than men34. Such a difference was not observed in this study. 
Levels of Independence, physical and psychological wellbeing 
seem to play an important role in one’s perception of one’s health status 
more than social and environmental factors.  
As in other studies the CD4 count has a positive correlation with 
QOL. 
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SUMMARY AND CONCLUSION 
 
 
An interventional study to find the improvement in Quality of 
Life of People Living with HIV/AIDS was done. The Tamil version of 
WHO QOL-HIV BREF was used. The scores were compared with the 
demographic charecteritics and the difference between pre ART and 
post ART scores were compared. 
There was a highly significant improvement in the Quality of 
Life of People Living with HIV/AIDS due to Anti retroviral therapy. 
Thus based on his study it can be concluded that Antiretroviral 
therapy not only prolongs life it also improves the quality of life of 
people living with HIV/AIDS.   
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LIMITATIONS 
  
 A single 3 month follow-up to assess the impact of ART on QOL 
is not sufficient. 
This group should be followed up every three months to study the 
effects of delayed complications, and effect of resistance of the virus to 
the drugs on the QOL. Due to time constraints this kind of continued 
follow-up could not be done.  
 The validity of the study would have been better if there was a 
control group which did not receive ART and again due to time 
constraints and ethical constraints this could not be done. 
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